Min Son of Hanol IP & Law outlines the new system’s key mechanisms and implications for evidence gathering in civil litigation, with a particular focus on technology-related disputes
Min Son of Hanol IP & Law analyses a Supreme Court ruling clarifying that prosecution history in a parent application can later limit the scope of divisional patent claims
A landmark case involving the remodelling of luxury brand bags at the owner’s request has established legal principles on the trademark implications of such services, explains Min Son of Hanol IP & Law
Min Son of Hanol IP & Law explains how the decision clarifies that multiple-word trademarks can infringe if an element serves as an essential distinctive part
Min Son of Hanol IP & Law explains why the ruling by South Korea’s Intellectual Property High Court marks a key development in online patent enforcement
Min Son of Hanol IP & Law explains an Intellectual Property High Court decision addressing the applicability of the abuse of right doctrine in a design invalidation action
Min Son of Hanol IP & Law analyses a ruling that clarifies the scope of patent infringement, territoriality limits, and research exemptions in a cross-border dispute over Pfizer’s pneumococcal vaccine
Min Son of Hanol IP & Law summarises a Korean Supreme Court ruling on when consumer surveys are admissible in trademark litigation and outlines key takeaways for ensuring survey credibility and evidentiary value
Min Son of Hanol IP & Law explains how a Patent Act revision empowers South Korean patentees to take direct action against export-based infringement, enhancing enforcement and aligning the law with other intellectual property regimes
Min Son of Hanol IP & Law explains that the regime will limit extensions to one patent per approval and cap extended periods at 14 years from the date of marketing authorisation
Min Son of Hanol IP & Law says pharmaceutical R&D in South Korea should be enhanced on the introduction of a clearer legal framework that offers improved market protection for new and modified drugs
